Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
MYCN oncogene amplification is an established indicator of the aggressiveness of neuroblastomas; it is used internationally for stratifying patients for therapy. The present study shows that high levels of MYCN DNA sequences are present in the peripheral blood of patients with MYCN-amplified neuroblastomas. Circulating MYCN DNA may be a powerful and noninvasive prognostic marker at the time of diagnosis. Furthermore, preliminary data strongly suggest that the release of MYCN sequences in the peripheral blood is an early process in disease progression, permitting us to propose this novel marker for the follow-up of patients after chemotherapy.
Combaret
Valérie
V
Centre Léon Bérard, 69008 Lyon, France.
Audoynaud
Carole
C
Iacono
Isabelle
I
Favrot
Marie-Christine
MC
Schell
Matthias
M
Bergeron
Christophe
C
Puisieux
Alain
A
D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D002648:Child; D004273:DNA, Neoplasm / Q000097:blood*; D005784:Gene Amplification; D006801:Humans; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000097:blood / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011379:Prognosis
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins